A partnership comprising TransCode Therapeutics and Quantum Leap Healthcare Collaborative has submitted an investigational ...

Submits IND Amendment For Planned Phase 2A Trial Of TTX-MC138 In Colorectal Cancer. TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug (“IND”) application ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics ...

Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D., Chief Operating Officer, will present at the Guggenheim Emerging ...

PTC Therapeutics, Inc. announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration ...

A Bulgarian scientist has developed a drug that halts the growth of cancer and prevents metastases from spreading to other ...

Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs. The company plans for its shares to trade on the Nasdaq Global Market under the symbol ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer led to a significant improvement in overall ...

TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive ...